Gennadiy D. Telegeev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gennadiy D. Telegeev has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Svitlana V. Antonenko
Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150, Zabolotnogo Str., 03143 Kyiv, Ukraine
3 shared publications - Aladdin Y. Shchaslyvyi
Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150, Zabolotnogo Str., 03143 Kyiv, Ukraine
2 shared publications - D. S. Gurianov
Інститут молекулярної біології і генетики НАН України, Україна, 03143, м Київ, вул. Акад. Заболотного, 150
2 shared publications - Mykhailo Dybkov
The Institute of Molecular Biology and Genetics, National Academy of Science of Ukraine, 03143 Kyiv, Ukraine
2 shared publications - Svitlana V. Antonenko
Institute of Molecular Biology and Genetics of Natl. Acad. Sci. of Ukraine, Ukraine, 03143, Kyiv, Akad. Zabolotnogo str., 150
2 shared publications - A. M. Gilfanova
Department of Pediatrics, Immunology, Infectious and Rare Diseases, International European University, Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 16 March 2026
- Published by IntechOpen
New Approaches to the Treatment of Chronic Myeloid Leukemia
While the specific inhibitors of BCR-ABL tyrosine kinase activity have gained well-deserved recognition in the frontline therapy of chronic myeloid leukemia (CML), acquired therapy resistance represents a serious problem, preventing long-term remission in CML patients. Moreover, in some patients, the resistance mechanisms are BCR-ABL-independent. Therefore, the search for alternative and complementary therapies is currently in the spotlight. The differentiation therapy may represent one of the possible approaches. Alpha-tocopherol may be one of the agents possessing differentiation potential in CML blast cells. We demonstrated that alpha-tocopherol and G-CSF upregulate the expression of several genes associated with the differentiation of K562 CML cells in vitro, in particular, the gene coding for the myeloid master regulator transcription factor C/EBPα. At the same time, a significant down-regulation of the expression of genes associated with the stemness phenotype, such as SNAI1, ALPP, and POU5F1 was observed. Other possible targets may be searched among the enzymes preventing the degradation of the BCR-ABL protein. The data on the specific inhibition of deubiquitinase USP1 activity in vitro in K562 cells have been presented. A vast array of other targetable enzymes interacting with the BCR-ABL protein and affecting its stability and activity remains an extensive field for further study. A putative role of protein phosphatase 2A in this context is discussed.
- 16 March 2026
- Published by IntechOpen
Open AccessNew Approaches to the Treatment of Chronic Myeloid Leukemia
While the specific inhibitors of BCR-ABL tyrosine kinase activity have gained well-deserved recognition in the frontline therapy of chronic myeloid leukemia (CML), acquired therapy resistance represents a serious problem, preventing long-term remission in CML patients. Moreover, in some patients, the resistance mechanisms are BCR-ABL-independent. Therefore, the search for alternative and complementary therapies is currently in the spotlight. The differentiation therapy may represent one of the possible approaches. Alpha-tocopherol may be one of the agents possessing differentiation potential in CML blast cells. We demonstrated that alpha-tocopherol and G-CSF upregulate the expression of several genes associated with the differentiation of K562 CML cells in vitro, in particular, the gene coding for the myeloid master regulator transcription factor C/EBPα. At the same time, a significant down-regulation of the expression of genes associated with the stemness phenotype, such as SNAI1, ALPP, and POU5F1 was observed. Other possible targets may be searched among the enzymes preventing the degradation of the BCR-ABL protein. The data on the specific inhibition of deubiquitinase USP1 activity in vitro in K562 cells have been presented. A vast array of other targetable enzymes interacting with the BCR-ABL protein and affecting its stability and activity remains an extensive field for further study. A putative role of protein phosphatase 2A in this context is discussed.
- Open Access
- 2 July 2025
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Faktori eksperimental'noi evolucii organizmiv
- Vol. 36, 69-74
Generation of recombinant constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2 as key tools for studying the domain organization of USP1 and its interaction with the oncoprotein Bcr-Abl
Aim. The aim of this study is to generate recombinant constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2, essential for investigating the domain organization of the USP1 protein, determining their role in USP1 function, and analyzing their interaction with the oncoprotein Bcr-Abl. Methods. Standard molecular cloning techniques were employed, including polymerase chain reaction (PCR), ligation, restriction enzyme digestion, as well as DNA extraction and purification methods. Results. The genetic constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2, encoding key domains of the USP1 protein, were successfully designed and obtained. Conclusions. The generated genetic constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2 will be utilized to study the role of these domains in USP1 function, its subcellular localization, and the formation of the Bcr-Abl/USP1 protein complex. These findings will contribute to a better understanding of the role of USP1 in cellular processes and facilitate the development of novel therapeutic approaches for the treatment of chronic myeloid leukemia (CML).
- 2 July 2025
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Faktori eksperimental'noi evolucii organizmiv
- Vol. 36, 69-74
Open AccessGeneration of recombinant constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2 as key tools for studying the domain organization of USP1 and its interaction with the oncoprotein Bcr-Abl
Aim. The aim of this study is to generate recombinant constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2, essential for investigating the domain organization of the USP1 protein, determining their role in USP1 function, and analyzing their interaction with the oncoprotein Bcr-Abl. Methods. Standard molecular cloning techniques were employed, including polymerase chain reaction (PCR), ligation, restriction enzyme digestion, as well as DNA extraction and purification methods. Results. The genetic constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2, encoding key domains of the USP1 protein, were successfully designed and obtained. Conclusions. The generated genetic constructs pECFP-C3-USP1-domain-1 and pECFP-C3-USP1-domain-2 will be utilized to study the role of these domains in USP1 function, its subcellular localization, and the formation of the Bcr-Abl/USP1 protein complex. These findings will contribute to a better understanding of the role of USP1 in cellular processes and facilitate the development of novel therapeutic approaches for the treatment of chronic myeloid leukemia (CML).
- 25 November 2024
- Published by Allerton Press in Cytology and Genetics
- Vol. 58 (6) , 554-559
Overcoming Antibiotic Resistance to Tetracycline in Staphylococcus aureus by Gold and Silver Nanoparticles
The use of tetracyclines in medicine, veterinary medicine, and stock raising has led to the spread of bacterial resistance to tetracycline, particularly am
- 25 November 2024
- Published by Allerton Press in Cytology and Genetics
- Vol. 58 (6) , 554-559
Overcoming Antibiotic Resistance to Tetracycline in Staphylococcus aureus by Gold and Silver Nanoparticles
The use of tetracyclines in medicine, veterinary medicine, and stock raising has led to the spread of bacterial resistance to tetracycline, particularly am
- Open Access
- 25 September 2024
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Faktori eksperimental'noi evolucii organizmiv
- Vol. 34, 88-94
Features of Usp1 expression and localization in different types of malignant neoplasms
Aim. Malignant neoplasms pose a significant challenge in medicine, requiring a deep understanding of the molecular mechanisms underlying their pathogenesis. This study aimed to investigate the expression profile and subcellular localization of ubiquitin-specific protease 1 (USP1) in various types of cancer. Methods. Using the TCGA database, an analysis of USP1 expression was conducted across different cancer types. Immunofluorescence analysis with confocal microscopy was utilized to determine the subcellular localization of USP1 in chronic myeloid leukemia (CML) and prostate cancer cells. Results. Bioinformatic analysis revealed heterogeneous USP1 expression, with increased levels observed in acute myeloid leukemia, esophageal carcinoma, and glioblastoma multiforme. Immunofluorescence analysis confirmed nuclear localization of USP1 in CML cells and showed that inhibiting USP1 interaction with UAF1 using ML323 disrupts its transport to the nucleus. Prostate cancer cells exhibited both nuclear and atypical cytoplasmic USP1 localization, suggesting alterations in its expression, interaction with UAF1, and disruption of signaling pathways. Conclusions. USP1 plays a multifaceted role in cancer processes, with dysregulation of its expression and localization associated with tumorigenesis. Targeting USP1 holds therapeutic potential for cancer treatment.
- 25 September 2024
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Faktori eksperimental'noi evolucii organizmiv
- Vol. 34, 88-94
Open AccessFeatures of Usp1 expression and localization in different types of malignant neoplasms
Aim. Malignant neoplasms pose a significant challenge in medicine, requiring a deep understanding of the molecular mechanisms underlying their pathogenesis. This study aimed to investigate the expression profile and subcellular localization of ubiquitin-specific protease 1 (USP1) in various types of cancer. Methods. Using the TCGA database, an analysis of USP1 expression was conducted across different cancer types. Immunofluorescence analysis with confocal microscopy was utilized to determine the subcellular localization of USP1 in chronic myeloid leukemia (CML) and prostate cancer cells. Results. Bioinformatic analysis revealed heterogeneous USP1 expression, with increased levels observed in acute myeloid leukemia, esophageal carcinoma, and glioblastoma multiforme. Immunofluorescence analysis confirmed nuclear localization of USP1 in CML cells and showed that inhibiting USP1 interaction with UAF1 using ML323 disrupts its transport to the nucleus. Prostate cancer cells exhibited both nuclear and atypical cytoplasmic USP1 localization, suggesting alterations in its expression, interaction with UAF1, and disruption of signaling pathways. Conclusions. USP1 plays a multifaceted role in cancer processes, with dysregulation of its expression and localization associated with tumorigenesis. Targeting USP1 holds therapeutic potential for cancer treatment.
- Top Cited PapersOpen Access
- 16 August 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (8) , 1077
Comprehensive Review of Chronic Stress Pathways and the Efficacy of Behavioral Stress Reduction Programs (BSRPs) in Managing Diseases
The connection between chronic psychological stress and the onset of various diseases, including diabetes, HIV, cancer, and cardiovascular conditions, is well documented. This review synthesizes current research on the neurological, immune, hormonal, and genetic pathways through which stress influences disease progression, affecting multiple body systems: nervous, immune, cardiovascular, respiratory, reproductive, musculoskeletal, and integumentary. Central to this review is an evaluation of 16 Behavioral Stress Reduction Programs (BSRPs) across over 200 studies, assessing their effectiveness in mitigating stress-related health outcomes. While our findings suggest that BSRPs have the potential to enhance the effectiveness of medical therapies and reverse disease progression, the variability in study designs, sample sizes, and methodologies raises questions about the generalizability and robustness of these results. Future research should focus on long-term, large-scale studies with rigorous methodologies to validate the effectiveness of BSRPs.
- 16 August 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (8) , 1077
Top Cited PapersOpen AccessComprehensive Review of Chronic Stress Pathways and the Efficacy of Behavioral Stress Reduction Programs (BSRPs) in Managing Diseases
The connection between chronic psychological stress and the onset of various diseases, including diabetes, HIV, cancer, and cardiovascular conditions, is well documented. This review synthesizes current research on the neurological, immune, hormonal, and genetic pathways through which stress influences disease progression, affecting multiple body systems: nervous, immune, cardiovascular, respiratory, reproductive, musculoskeletal, and integumentary. Central to this review is an evaluation of 16 Behavioral Stress Reduction Programs (BSRPs) across over 200 studies, assessing their effectiveness in mitigating stress-related health outcomes. While our findings suggest that BSRPs have the potential to enhance the effectiveness of medical therapies and reverse disease progression, the variability in study designs, sample sizes, and methodologies raises questions about the generalizability and robustness of these results. Future research should focus on long-term, large-scale studies with rigorous methodologies to validate the effectiveness of BSRPs.
- Top Cited PapersOpen Access
- 5 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1416
Current State of Human Gene Therapy: Approved Products and Vectors
In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like melanoma, pancreatic cancer, and a host of other ailments, are now being addressed at their root cause—the genetic level. Presently, the gene therapy landscape stands adorned with 22 approved in vivo and ex vivo products, including IMLYGIC, LUXTURNA, Zolgensma, Spinraza, Patisiran, and many more. In this comprehensive exploration, we delve into a rich assortment of 16 drugs, from siRNA, miRNA, and CRISPR/Cas9 to DNA aptamers and TRAIL/APO2L, as well as 46 carriers, from AAV, AdV, LNPs, and exosomes to naked mRNA, sonoporation, and magnetofection. The article also discusses the advantages and disadvantages of each product and vector type, as well as the current challenges faced in the practical use of gene therapy and its future potential.
- 5 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1416
Top Cited PapersOpen AccessCurrent State of Human Gene Therapy: Approved Products and Vectors
In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like melanoma, pancreatic cancer, and a host of other ailments, are now being addressed at their root cause—the genetic level. Presently, the gene therapy landscape stands adorned with 22 approved in vivo and ex vivo products, including IMLYGIC, LUXTURNA, Zolgensma, Spinraza, Patisiran, and many more. In this comprehensive exploration, we delve into a rich assortment of 16 drugs, from siRNA, miRNA, and CRISPR/Cas9 to DNA aptamers and TRAIL/APO2L, as well as 46 carriers, from AAV, AdV, LNPs, and exosomes to naked mRNA, sonoporation, and magnetofection. The article also discusses the advantages and disadvantages of each product and vector type, as well as the current challenges faced in the practical use of gene therapy and its future potential.
- 16 June 2022
- Published by Allerton Press in Cytology and Genetics
- Vol. 56 (3) , 226-235
Polymorphisms of Genes Associated with Intracellular Signaling Pathways in Juvenile Idiopathic Arthritis
The aim of the study was to determine nucleotide sequence changes in the genes associated with the activation of intracellular signaling molecules and the
- 16 June 2022
- Published by Allerton Press in Cytology and Genetics
- Vol. 56 (3) , 226-235
Polymorphisms of Genes Associated with Intracellular Signaling Pathways in Juvenile Idiopathic Arthritis
The aim of the study was to determine nucleotide sequence changes in the genes associated with the activation of intracellular signaling molecules and the
- 14 November 2017
- Published by Taylor & Francis
- p. 183-193
Dextran-Polyacrylamide as Nanocarrier for Targeted Delivery of Anticancer Drugs into Tumor Cells
Drug targeting to specific organs and tissues is one of the crucial endeavors of modern pharmacotherapy. Controlled targeting at the site of action and reduced time of exposure of non-targeted tissues increase the efficacy of the treatment and reduce toxicity and side effects, improving compliance and convenience. Nanocarriers based on the branched copolymers dextran- graft-polyacrylamide were synthesized and characterized and were tested on phagocytic cells. It was shown that these nanoparticles are actively captured by phagocytic cells, and that they are not cytotoxic (90% ± 2% live cells at 0.01 mkg/ml). The polymer nanoparticles loaded with cisplatinum at different concentrations from 0.01 to 0.1 mkd/ml yielded a percentage of living cells between 28% and 76%. Taking into account that our nanoparticles will act mainly on malignant phagocytic cells and do not affect healthy cells, they can thus potentially be used for the therapeutic treatment of tumor cells having phagocytic activity.
- 14 November 2017
- Published by Taylor & Francis
- p. 183-193
Dextran-Polyacrylamide as Nanocarrier for Targeted Delivery of Anticancer Drugs into Tumor Cells
Drug targeting to specific organs and tissues is one of the crucial endeavors of modern pharmacotherapy. Controlled targeting at the site of action and reduced time of exposure of non-targeted tissues increase the efficacy of the treatment and reduce toxicity and side effects, improving compliance and convenience. Nanocarriers based on the branched copolymers dextran- graft-polyacrylamide were synthesized and characterized and were tested on phagocytic cells. It was shown that these nanoparticles are actively captured by phagocytic cells, and that they are not cytotoxic (90% ± 2% live cells at 0.01 mkg/ml). The polymer nanoparticles loaded with cisplatinum at different concentrations from 0.01 to 0.1 mkd/ml yielded a percentage of living cells between 28% and 76%. Taking into account that our nanoparticles will act mainly on malignant phagocytic cells and do not affect healthy cells, they can thus potentially be used for the therapeutic treatment of tumor cells having phagocytic activity.
- Open Access
- 1 September 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1347-61
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
Peer reviewed article authored by (Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A). Read article or submit your manuscript for publishing.
- 1 September 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1347-61
Open AccessEmerging targets in cancer management: role of the CXCL12/CXCR4 axis
Peer reviewed article authored by (Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A). Read article or submit your manuscript for publishing.